BLOG DA SOCIEDADE
BRASILEIRA DE IMUNOLOGIA
Acompanhe-nos:

Translate

sábado, 15 de outubro de 2011

Palestras ImunoFoz2011 - Foo Yew Liew


Dr. Liew repassou para a audiência todo o histórico da citocina IL-33 - desde sua descrição na década de 1990 em células Th2, até os estudos contemporâneos - realizados em seu laboratório, bem como suas colaboração com alguns grupos brasileiros, como aqueles chefiados pelos professores Fernando Cunha e João Santana.




Entrevistas ImunoFoz2011 - Histórico




Adriana Bonomo
Alexandre Basso
Alice Yu
Ana Lepique
Christopher Hunter
Claudia Brodskyn
Craig Roy
Cristina Bonorino
Daniel Carvalho
Francis Chan
João Santana Silva
Jonathan Powell
Karina Bortoluci
Koichi Kobayashi
Leonardo Riella
Lucas Carvalho 
Lúcia Faccioli
Marco Antonio Campos
Marc Peters-Golden
Matthias von Herrath
Mihály Józsi
Momtchilo Russo
Paolo Fiorina
Paul Kubes
Pedro Persechini
Ramon Kaneno
Ricardo Gazzinelli  
Rudolf Zinkernagel
Tatiana Fraga

sexta-feira, 14 de outubro de 2011

É verdade que o padrão da sua microbiota intestinal afeta a sua memória, além do seu humor?

Há algum tempo, a Cris Caldas escreveu um post em que comentava uma revisão interessante publicada no ano passado pelo grupo liderado por John Bienenstock. Relembrando este post da Cris, nesta revisão, os autores argumentam sobre a possibilidade de que alterações comportamentais, ou estados de humor, estejam diretamente relacionados ao padrão da microbiota intestinal. Relatam que a microbiota é fonte de uma série de substâncias que podem afetar diretamente o epitélio intestinal, as aferências nervosas presentes no órgão e as células do sistema imune presentes na mucosa. A relação entre microbiota e a resposta imune local na mucosa do intestino tem atraído muita atenção nos últimos tempos. Vários artigos têm destacado o desenvolvimento preferencial de diferentes subtipos de células T CD4+ dependendo de que tipo de bactéria coloniza o intestino de camundongos. O Dario também já escreveu posts sobre isso (aqui e aqui). Assim, há trabalhos que reportam bactérias que poderiam favorecer a expansão ou geração de células T reguladoras e artigos que apontam outras bactérias que favoreceriam a produção de IL-17 ou IL-22 no intestino. Uma das bactérias descritas como capazes de induzir respostas imunes no intestino com predominância de IL-17 é a Citrobacter rodentium, uma gram negativa. Neste caso, a morte por apoptose de células infectadas seria o fator responsável pela geração de células Th17. Até que ponto essas diferentes respostas imunes geradas em função de diferentes microbiotas poderiam estar diretamente associadas a mudanças de humor ou de comportamento? E memória? Não a imunológica, mas aquela com sede no sistema nervoso central mesmo. Seria esta influenciada pelos mesmos fatores? Um artigo publicado em março de 2011 na revista Gut levanta essa questão. Os autores usaram modelos experimentais para investigar a memória de animais germ-free e de animais infectados com Citrobacter rodentium. Os animais infectados, a princípio, não apresentaram alterações de memória quando comparados aos controles. No entanto, quando expostos a uma situação de estresse, os animais infectados apresentaram prejuízo de memória. A deficiência de memória deixou de ser observada quando os animais foram tratados com probióticos. Curiosamente, os animais germ-free, independentemente de passarem ou não por situação de estresse, também apresentaram deficiências de memória que puderam ser observadas em dois modelos experimentais. O artigo não faz conexões entre esses achados e a resposta imune em animais infectados ou germ-free. Será que elas existem?

Gareau MG, Wine E, Rodrigues DM, Cho JH, Whary MT, Philpott DJ, Macqueen G,
Sherman PM. Bacterial infection causes stress-induced memory dysfunction in mice.
Gut. 2011 Mar;60(3):307-17.

Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a
commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A. 2010
Jul 6;107(27):12204-9.

Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb
KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda
K, Littman DR. Induction of intestinal Th17 cells by segmented filamentous
bacteria. Cell. 2009 Oct 30;139(3):485-98

Torchinsky MB, Garaude J, Martin AP, Blander JM. Innate immune recognition of
infected apoptotic cells directs T(H)17 cell differentiation. Nature. 2009 Mar
5;458(7234):78-82.


Entrevistas ImunoFoz2011 - Leonardo Riella

SBlogI entrevista:

 
Dr. Leonardo V. Riella
Harvard Medical School, EUA





SBlogI - What is the theme of your lecture at ImunoFoz 2011?
Riella, L. V. - Novel role of the Notch pathway in graft rejection.

SBlogI - What is the main finding or conclusion that will be emphasized?
Riella, L. V. - Different Notch signals are able to drive complete opposite alloimmune responses in the transplant setting, leading to either rejection or improvement in graft survival.

SBlogI - What is the significance of this finding?
Riella, L. V. - Targeting the Notch pathway has a great promise for immunomodulation of the immune response.

SBlogI - What are the future perspectives in this area?
Riella, L. V. - Improvement of monoclonal antibodies and inhibitory drugs will advance the field in multiple areas, including oncology, transplantation and infectious disease. 

SBlogI - What are the challenges in this area? Are there controversies? Opponent hypotheses?
Riella, L. V. - Challenges are related to the broad expression of the Notch pathway in multiple tissues, requiring the development of more selective agents to avoid toxicity.  

SBlogI - Any suggestions for background reading?
Riella, L. V. - 
Amsen et al. The different faces of Notch in T-helper-cell differentiation. Nat Rev Immunol 2009;0(2):116-124.

quinta-feira, 13 de outubro de 2011

Entrevistas ImunoFoz2011 - Paul Kubes

SBlogI entrevista:

 
Dr. Paul Kubes
University of Calgary, Canadá




  
SBlogI - What is the theme of your lecture at ImunoFoz 2011? 
Kubes, P. - How do white cells get to sites of inflammation.

SBlogI - What is the main finding or conclusion that will be emphasized? 
Kubes, P. - Understanding the process of how white cells get to sites of inflammation could function to help us eliminate this event and reduce inflammation. This could translate into novel therapy for this devastating set of inflammatory diseases.

SBlogI - What are the future perspectives in this area?
Kubes, P. - We hope to fully elucidate the mechanisms and look to find novel drugs through high throughput screens.

SBlogI - What are the challenges in this area? Are there controversies? Opponent hypotheses? 
Kubes, P. - The real challenge is to ensure we do not impair healing and repair mechanisms while we block inflammation.  These are intimately linked.

SBlogI - Any suggestions for background reading?
Kubes, P. - McDonald et al., Science 2010. 

quarta-feira, 12 de outubro de 2011

Vejam, vejam, vejam .....

Caros, vejam artigos sobre o Brasil na Nature Medicine


e vários outros.

Imunologia ganha Premio Destaque do Ano na Iniciação Científica


O Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq/MCTI) divulgou o resultado do 9º Prêmio Destaque do Ano na Iniciação Científica. A escolha dos agraciados foi feita por três Comissões Julgadoras, uma para cada grande área do conhecimento, que se reuniram na terça-feira (28) em Brasília. Nesta 9º edição do Prêmio participaram 89 instituições, sendo 73 universidades e 16 institutos de pesquisa. As instituições encaminharam ao CNPq 162 relatórios de bolsistas de Iniciação Científica, dos quais 133 foram validados, sendo: 53 da área de Ciências da Vida; 43 das Ciências Humanas e Sociais, Letras e Artes; e 37 da área de Ciências Exatas, da Terra e Engenharia.
A cerimônia de entrega do Prêmio será no próximo dia 18 de outubro na abertura da Semana Nacional de Ciência, Tecnologia e Inovação.
CIÊNCIAS DA VIDA:
1º lugar : Paula Seixas Mello , da Universidade Federal de Minas Gerais (UFMG), tendo como orientadora a professora Leda Quercia Vieira, com o trabalho intitulado: “Caracterização de Modelo Murino (TNFRp55-/-) Para Estudo de Ulcerações Crônicas Causadas por Leishmania Major”.
Ver trabalho

___
Assessoria de Comunicação Social do CNPq


EpHLA

Os Professores da Universidade Federal do Piauí, Dr. Luiz Cláudio Demes da Mata Sousa, Dr. Adalberto Socorro da Silva e Dra. Semiramis Jamil Hadad do Monte (coordenadora do Laboratório de Imunogenética e Biologia Molecular da Universidade Federal do Piauí) juntamente com seus colaboradores publicaram este mês no periódico Transplant immunology, o artigo intitulado:

EpHLA: An innovative and user-friendly software automating the HLAMatchmaker algorithm for antibody analysis.

Este software automatiza o uso do algortimo HLAmatchmaker, desenvolvido por René Duquesnoy, diminuindo o tempo necessário para a determinação de mismatchs aceitáveis (com base no conceito de eplets), de 3 horas para 5 minutos!

No artigo, relatamos dois casos interessantes cujo entendimento foi facilitado pelo emprego do software. A seguir colocamos os casos na íntegra, mas convidamos o leitor para uma leitura do artigo completo, que está disponível on line para open acess.

Caso 1.

A 55-year-old man with CDC assay negative received a kidney transplant from his mother. Eight years after transplantation he lost the kidney by chronic rejection. A serum screen of this recipient using single class I and II allele SPA Luminex panels (Labscreen; OneLambda, Canoga Park, CA) revealed the presence of anti-class II donor specific antibodies (anti-DRB5*02:02) as well as non-donor specific antibodies .

We asked why the recipient developed antibodies against antigens to which he was never exposed. In order to solve this problem we used the EpHLA software. A closer view of results in the EpHLA's Histocompatibility Map report showed that all HLA molecules to which the recipient developed antibodies share eplets with DRB5*02:02 from the immunizer. Interestingly, the DRB5*02:02 molecule has three potentially immunogenic eplets: 6C, 71QAA, 108T3. We noted that while 6C eplet appears only on DRB5*02:02 molecule, the 71QAA eplet is shared by molecules of serum group DR15 (DRB1*15:01, DRB1*15:02, DRB1*15:03) and the 108T3 eplet is shared by DRB5*01:01.

Thus, we were able to identify the epitopes targeted by the recipient's HLA antibodies using the EpHLA software, and the alleles DRB5*02:02, DRB5*01:01, DRB1*15:01, DRB1*15:02, DRB1*15:03 are the unacceptable mismatches for this case; they are associated to a 28% cPRA.

Caso 2.

A 35-year-old female in chronic hemodialysis, enrolled in the related renal transplantation program with two potential donors (brothers). The donors were typed as identical HLA each other and distinct as regards the recipient. The result of the T and B

CDC assays were positive to both donors. Four years later, the CDC assays performed with the same donors were negative and flow cytometry crossmatches were positive for T and B cells.

The SPA results using current serum showed preformed antibodies directed to a myriad of different class I and II HLA antigens (cPRA=91%). The possible immunization events were blood transfusions and three gestations from the same husband, whose HLA typing is shown in Table 2. A closer examination of the SPA results revealed:

(i) specific antibodies against the husband's HLA mismatches, including allele A*02:01 (MFI =8,994), and (ii) antibodies against potential donors' HLA antigens, including allele A*68:02 (MFI =12,353). Because A*02:01 and A*68:02 alleles belong to the same CREG, we reasoned that such alleles could share the same eplet targeted by the recipient's HLA antibodies.

We tested our hypothesis using the EpHLA software analyzing recipient versus immunizer, and then versus potential donors. We found that the recipient HLA antibodies recognize the pair of eplets 142MT +145KHA. Such eplets are shared by the HLA allele A*02:01 from the immunizer and allele A*68:02 from potential donors. As showed, the immunizer and potential donors share the same beta subunit in the HLA DQ molecule (DQB1*03:01), however combined to different alpha subunits. Such beta subunit presents an only potentially immunogenic eplet: 45EV. Nevertheless, as the MFI value of the HLA heterodimer DQA1*02:01–DQB1*03:01 of the potential donors is 921, the immunological risk is low for class II HLA. Contrariwise, we were able to detect a strong reactivity against A*68:02, representing a high immunological risk for antibody-mediated rejection.

As there is no agreement upon current CDC assay with the flow cytometry crossmatch and SPA results, we believe that the recipient has a mixture of antibodies with a prevalence of non-fixing complement isotypes, or the titles of the fixing complement antibodies present in the current serum were not enough to activate the classic pathway of the complement system. Thus, the potential donors' allele A*68:02 is considered one of the unacceptable mismatches for this recipient. As the calculated PRA was 91%, this case exemplifies the importance of using the Acceptable Mismatch approach.

Adalberto S. da Silva


Entrevistas ImunoFoz2011 - Mihály Józsi

SBlogI entrevista:

 
Dra. Mihály K. Józsi
Hans Knöll Institute, Alemanha





SBlogI - What is the theme of your lecture at ImunoFoz 2011?  
Józsi, M. K. - Crosstalk between pentraxins and the complement system.  

SBlogI - What is the main finding or conclusion that will be emphasized?
Józsi, M. K. - While pentraxins activate complement, simultaneously binding complement inhibitors prevent the harmful effects of overwhelming activation. 

SBlogI - What is the significance of this finding? 
Józsi, M. K. - Certain disease-associated variants of complement regulators show reduced pentraxin binding, which is likely involved in pathophysiology.   

SBlogI - What are the future perspectives in this area?
Józsi, M. K. - Role of these interactions  in inflammatory, autoimmune and infectious diseases, and the relevance for therapy should be explored.  

SBlogI - Any suggestions for background reading?
Józsi, M. K. - 
Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2010 Mar;28:157-83.
Sjöberg AP, Trouw LA, Blom AM. Complement activation and inhibition: a delicate balance. Trends Immunol. 2009 Feb;30(2):83-90.
Mihlan M, Stippa S, Józsi M, Zipfel PF. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ. 2009 Dec;16(12):1630-40.
Nauta AJ, Daha MR, van Kooten C, Roos A. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol. 2003 Mar;24(3):148-54.

terça-feira, 11 de outubro de 2011

Entrevistas ImunoFoz2011 - Matthias von Herrath

SBlogI entrevista:


Dr. Matthias G. von Herrath
La Jolla Institute for Allergy and Immunology, EUA




SBlogI - What is the theme of your lecture at ImunoFoz 2011?
von Herrath, M. G. - We have been studying, in mice and humans, what the role of CD8 immune cells is in type 1 diabetes. These cells are found in human islets and, based on our recent data, bear specificity for islet (beta-cell) antigens. islets that harbor these cells usually also over-express high levels of MHC class I. 

SBlogI - What is the main finding or conclusion that will be emphasized?
von Herrath, M. G. - In mouse studies, we can show that islet reactive CD8 cells only kill beta-cells well, when there are high levels of MHC class i expressed, making this a likely crucial pathogenetic event. In addition, we can show that viral infections (for example enteroviruses) of beta cells and islets can lead to upregulation of MHC class I. Thus, local viral infections might contribute to the development of diabetes my 'unmasking' beta cells to destruction by CD8 cells from the immune system. 

SBlogI - What are the future perspectives in this area?
von Herrath, M. G. - Lowering of MHC class i on beta cells, for example by preventing viral infections of the pancreas (ie via vaccines) might be helpful to prevent development type 1 diabetes. 

SBlogI - What are the challenges in this area? Are there controversies? Opponent hypotheses?
von Herrath, M. G. - Viruses can also prevent diabetes (as we have shown), thus the key is to differentiate between the enhancing (likely more severe) versus the protective (likely milder) infections. Suitable vaccines to prevent these viral infections might be helpful. 

SBlogI - Any suggestions for background reading?
von Herrath, M. G. - Seewald et al. Diabetes 2000, Filippi et al. JCI 2009, hopefully Coppieters et al. JEM 2011.
©SBI Sociedade Brasileira de Imunologia. Desenvolvido por: